Research Topics
Species | Massimo FedericoSummaryAffiliation: University of Modena and Reggio Emilia Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy
J Clin Oncol 27:4555-62. 2009....
Cancer incidence in people with residential exposure to a municipal waste incinerator: an ecological study in Modena (Italy), 1991-2005Massimo Federico
Medical Oncology II, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, Italy
Waste Manag 30:1362-70. 2010..In conclusion, bearing in mind the intrinsic limits of the study, the results suggest that there is no detectable increase of cancer risk for people living in proximity to the Modena MWI...
R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana LinfomiMassimo Federico
Dipartimento di Oncologia ed Ematologia, Centro Oncologico Modenese, Universita di Modena e Reggio Emilia, Policlinico Via del Pozzo 71, 41100 Modena, Italy
J Clin Oncol 31:1506-13. 2013..CONCLUSION In this study, R-CHOP and R-FM were superior to R-CVP in terms of 3-year TTF and PFS. In addition, R-CHOP had a better risk-benefit ratio compared with R-FM...
Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experienceLaura Cortesi
Centro per lo Studio dei tumori familiari, Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Italy
BMC Cancer 6:210. 2006..However, screening modalities depend on the level of risk. Here we present an update of our screening programs based on risk classification...
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapyMassimo Federico
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Centro Oncologico Modenese, Via del Pozzo, 71 41100 Modena, Italy
J Clin Oncol 21:2320-5. 2003..To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should be included in the initial consolidative treatment of patients with advanced, unfavorable Hodgkin's lymphoma (HL)...
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 studyMassimo Federico
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
Eur J Haematol 76:217-29. 2006..To compare two different schedules of two different anthracycline-containing regimens, where length of treatment is modulated according to the international prognostic index (IPI) in patients with aggressive non-Hodgkin's Lymphoma (NHL)...
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi TrialMassimo Federico
Dipartimento di Oncologia ed Ematologia, Centro Oncologico Modenese, Universita di Modena e Reggio Emilia, Modena, Italy
J Clin Oncol 27:805-11. 2009....
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL studyMassimo Federico
Dipartimento di Oncologia ed Ematologia, Centro Oncologico Modenese, Universita di Modena e Reggio Emilia, Policlinico, Via del Pozzo 71, 41100 Modena, Italy
Haematologica 92:1482-8. 2007..The present study examined the influence of beta2M levels on overall survival (OS) of patients with follicular lymphoma (FL)...
Prognostic factors in low-grade non-Hodgkin lymphomasMassimo Federico
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Centro Oncologico Modenese, Via del Pozzo, 71 41100, Modena, Italy
Curr Hematol Malig Rep 4:202-10. 2009..The field of biologically specific associated parameters holds great potential but requires more research and work to produce translational results...
Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian womenLaura Cortesi
Department of Oncology and Hematology, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, Italy
Tumori 98:743-50. 2012..Our aim was to evaluate the prognosis of these phenotypes in the pre-trastuzumab era in a large cohort of Italian women...
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphomaStefano Sacchi
Department of Oncology and Hematology, University of Modena, Modena, Italy
Cancer 110:121-8. 2007..The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients with recurrent follicular lymphoma (FL)...
Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based studyLaura Cortesi
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
Int J Gynecol Cancer 19:1358-63. 2009..The aim of this study was to investigate the incidence of second primary tumors in patients with breast cancer (BC), with particular regard to bidirectional risk for endometrial cancer (EC)...
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern ItalyStefano Luminari
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
Hematol Oncol 25:189-97. 2007..The usefulness of a population-based approach to better characterizing different lymphoma subtypes is also demonstrated...
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancerLaura Cortesi
Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
BMC Cancer 10:90. 2010....
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based studyClaudia Mucciarini
Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
BMC Cancer 7:230. 2007..This study examined the incidence of GIST in the province of Modena, including pathologic features and clinical outcome...
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomasAlessia Bari
Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
Leuk Res 37:619-23. 2013..8×10(9)/L, hemoglobin<120g/L, albumin<35g/L) had a negative influence on outcome, but in multivariate analysis, monocytosis alone had a stronger association with poor OS...
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent yearsLaura Cortesi
Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
Int J Cancer 132:E58-65. 2013....
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort studyStefano Sacchi
Centro Oncologico Modenese, Policlinico, Largo del Pozzo 71, 4100 Modena Italy
Haematologica 93:1335-42. 2008..The aims of this study were to determine the incidence and time free of second cancers in this subset of patients...
Protein expression patterns associated with advanced stage ovarian cancerLaura Cortesi
Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
Electrophoresis 32:1992-2003. 2011..Moreover, this study suggests that calgranulin expression may be used as a diagnostic and/or prognostic biomarker...
Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based studyLaura Cortesi
Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
J Surg Oncol 106:399-405. 2012..The purpose of this study is to determine the adequate surgical treatment and prognosis of Nmic in a population-based series of breast cancer patients...
Identification of protein clusters predictive of response to chemotherapy in breast cancer patientsLaura Cortesi
Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
J Proteome Res 8:4916-33. 2009....
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeatLaura Cortesi
Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy
Breast Cancer Res Treat 134:435-41. 2012..Our collected evidence suggests that, although occurring in a highly conserved region, the BRCA1 V1687I variant is likely a benign sequence alteration...
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenariosIvan Rashid
Modena Cancer Registry, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
Stat Med 27:2145-58. 2008..The results of simulations could be useful for a quick identification of the most appropriate approach when estimating up-to-date cancer survival rates...
Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern ItalyStefano Luminari
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
Leuk Lymphoma 52:1689-96. 2011..33); the F-PET result was the only prognostic factor for overall survival (OS) (HR 14.2). This population-based study confirms the prognostic role of I-PET for FFS also in daily practice; the results of F-PET can be used to predict OS...
The role of anthracyclines in follicular lymphomasStefano Luminari
Oncologia Medica II, Dipartimento di Oncologia ed Ematologia, , Centro Oncologico Modenese, Modena, Italy
Leuk Lymphoma 47:2267-8. 2006
Hodgkin's disease: a quantitative evaluation by computed tomography of tumor burdenPietro Torricelli
Department of Radiology, University of Modena and Reggio Emilia, Policlinico, Via del Pozzo 71, I 41100 Modena, Italy
Clin Imaging 28:239-44. 2004..It is concluded that the CT-calculated TB is a reliable index showing good correlation with other commonly used prognostic parameters...
Prognostic tools in follicular lymphomasStefano Luminari
Centro Oncologico Modenese, Dipartimento integrato di Oncologia, Ematologia e Malattie dell Apparato Respiratorio, Universita di Modena e Reggio Emilia, Modena, Italy
Expert Rev Hematol 2:549-62. 2009..The progressive development of new and more effective therapies for the treatment of FL makes the study of prognosis a dynamic and evolving area of clinical research...
Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma projectMassimo Federico
Universita di Modena e Reggio Emilia, Modena, Italy
J Clin Oncol 31:240-6. 2013..The International Peripheral T-Cell Lymphoma Project was undertaken to better understand the subtypes of T-cell and natural killer (NK) -cell lymphomas...
Follicular lymphoma - treatment and prognostic factorsStefano Luminari
Department of Oncology, Hematology and Respiratory Diseases, L Università di Modena e Reggio Emilia UniMoRe, Modena, Italy
Rev Bras Hematol Hemoter 34:54-9. 2012..This review provides a general overview of the state of the art in the management of follicular lymphoma and also, a brief description regarding the current prognostic tools available for treatment decisions...
Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphomaStefano Luminari
Universita di Modena e Reggio Emilia, Modena, Italy
Hematol Rep 3:e4. 2011..The use of liposomal doxorubicin in combination regimens for other conditions, such as follicular lymphoma and splenic marginal zone lymphoma, is also under investigation, and early results are promising...
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasiasStefano Luminari
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Milan, Italy
Br J Haematol 121:772-4. 2003..49 months, P = 0.003)...
Prognosis of follicular lymphomasStefano Luminari
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
Hematol Oncol 24:64-72. 2006..Further data and large international cooperative studies are needed to translate into clinical practice the novel acquisitions of biology and therapeutics...
T-cell lymphomas in South america and europeMonica Bellei
Department of Oncology, Hematology and Respiratory Diseases, L Università di Modena e Reggio Emilia UniMoRe, Modena, Italy
Rev Bras Hematol Hemoter 34:42-7. 2012..These projects are the basis of forthcoming cooperative, large scale trials to detail biologic characteristics of each sub-entity and to possibly individuate targets for new therapies...
Prognosis of screen-detected breast cancers: results of a population based studyLaura Cortesi
Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Italy
BMC Cancer 6:17. 2006..However, the assessment of 5-year overall and event-free survival could represent an earlier measure of the efficacy of mammography screening program (MSP)...
Splenosis peritoneiStefano Luminari
Dipartimento di Oncologia ed Ematologia, , Modena, Italy
Br J Haematol 123:378. 2003
Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genesLaura Cortesi
Dipartimento di Oncologia ed Ematologia, , Italy
Eur J Hum Genet 11:210-4. 2003..The discovery of the BRCA2 mutation allowed us to alert the patient's daughter who, otherwise, could be falsely reassured since she had a negative BRCA1 test...
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical studyAndrea Gallamini
Struttura Complessa Ematologia Azienda Ospedaliera S Croce e Carle, Cuneo, Italy
Blood 103:2474-9. 2004..9% and 38.8%, respectively; group 3, 2 factors, with 5-year and 10-year OS of 32.9% and 18.0%, respectively; group 4, 3 or 4 factors, with a 5-year and 10-year OS of 18.3 and 12.6%, respectively (P< or =.0001; log-rank, 66.79)...
Follicular lymphoma international prognostic indexPhilippe Solal-Celigny
Centre Jean Bernard, 9 rue Beauverger, 72000 Le Mans, France
Blood 104:1258-65. 2004..Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments...
The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 casesLuigi Rigacci
Cattedra e Divisione di Ematologia, Universita di Firenze, Firenze, Italia
Leuk Lymphoma 44:1911-7. 2003..On the basis of these results anthracycline-containing regimens (ACR) should be considered as the standard treatment of patients with advanced follicular lymphoma...
Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio LinfomiPaolo G Gobbi
Medicina Interna e Oncologia Medica, Universita di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
Cancer 98:2393-401. 2003..The acknowledged effectiveness of vinblastine, bleomycin, and methotrexate (VBM) chemotherapy in patients with early-stage Hodgkin lymphoma has been associated with conflicting toxicity reports...
Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998Silvia Franceschi
Agency for Research on Cancer, Lyon, France
J Acquir Immune Defic Syndr 34:84-90. 2003..5% in 1993-1996 to 2.4% in 1997-1998, but IRs after AIDS could not be evaluated. On account of the marked decline of KS in men in 1997-1998, the overall burden of ADCs in Italy became similar in both genders...
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients Corrado Tarella
Dipartimento Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy
Cancer 97:2748-59. 2003....
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patientsPier Luigi Zinzani
Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
Haematologica 87:1258-64. 2002....
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumorsPaolo G Gobbi
Medicina Interna, Oncologia e Gastroenterologia, Universita di Pavia, IRCCS, Policlinico San Matteo, Piazzale Golgi no 2, 27100 Pavia, Italy
Clin Cancer Res 12:529-35. 2006..Late results, toxicity, and second tumor incidence were reviewed in all the patients treated...
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)Marco Lombardo
Dipartimento di Oncologia, Azienda Ospedaliera Santo Spirito, Pescara, Italy
Leuk Lymphoma 43:1795-801. 2002..In particular the BACOP schedule is a valid anthracycline-containing regimen, and in this respect suitable to be considered as a treatment option...
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei LinfomiLuca Baldini
Unità Operativa Ematologia 1, Centro G Marcora, Ospedale Maggiore, IRCCS, Via F Sforza 35, 20121 Milano, Italy
J Clin Oncol 21:1459-65. 2003..To evaluate the effect of epirubicin on therapeutic response and survival in patients with indolent nonfollicular B-cell lymphomas (INFL) treated with pulsed high-dose chlorambucil...
Stage-specific incidence of breast cancer before the beginning of organized screening programs in ItalyEva Buiatti
Tuscany Regional Health Agency, Florence, Italy
Cancer Causes Control 13:65-71. 2002..To measure stage-specific geographic and time variability of breast cancer in seven Italian areas before the onset of organized screening programs...
Lymphomas: Hodgkin and non-Hodgkin lymphomasMassimo Federico
Registro tumonr della Provincia di Modena
Epidemiol Prev 28:92-6. 2004..As regards non-Hodgkin lymphomas (16, 470 incident cases and 7,193 deaths), there is a significant increasing trend, in both sexes, both for incidence (more than 3 %/years) and mortality (about 2%/year)...
In situ breast cancer: incidence trend and organised screening programmes in ItalyAlessandro Barchielli
Epidemiology Unit, Local Health Unit 10, Via di San Salvi 12, 50135 Florence, Italy
Eur J Cancer 41:1045-50. 2005..Therefore, the effect of mammography on stage-specific incidence of CIS may be more marked than expected on the basis of the effect of screening programmes...
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trialUmberto Vitolo
Ematologia, Azienda Ospedaliera S Giovanni Battista, Corso Bramante 88, 10126 Turin, Italy
Haematologica 90:793-801. 2005....
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosisCarlo Visco
Department of Hematology, Ospedale S. Bortolo, Vicenza, Italy
Eur J Haematol 77:387-94. 2006....
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patientsGiuseppe Marotta
Hematology Unit, University of Siena, Siena, Italy
Eur J Haematol 77:109-13. 2006..CONCLUSIONS: From our data there does not appear to be any significant role for IFN-alpha in improving the proportion and the duration of CR in HCL patients previously treated with DCF...
National estimates of cancer patients survival in Italy: a model-based methodRiccardo Inghelmann
Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Reparto di Epidemiologia dei Tumori, Istituto Superiore di Sanita, Rome, Italy
Tumori 91:109-15. 2005..Moreover, to measure the degree of representativeness of cancer patient survival obtained from Italian cancer registries data...
Splenic marginal zone lymphoma: a prognostic model for clinical useLuca Arcaini
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy
Blood 107:4643-9. 2006..In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient...
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano LinfomiPaolo G Gobbi
Medicina Interna e Oncologia Medica, Universita di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
J Clin Oncol 23:9198-207. 2005....
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei LinfomiNicola Di Renzo
Unità Operativa di Ematologia ed Oncologia Medica, C R O B, Ospedale Oncologico Regionale, Rionero in Vulture, PZ, Italy
Leuk Lymphoma 47:473-9. 2006..This regimen should be tested in less heavily pre-treated patients and probably in combination with new active agents such Rituximab. Further developments of this combination are warranted...
Revised response criteria for malignant lymphomaBruce D Cheson
Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
J Clin Oncol 25:579-86. 2007..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
Estimated and observed cancer incidence in Italy: a validation studyRiccardo Capocaccia
Reparto di Epidemiologia dei Tumori, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanita, Rome, Italy
Tumori 93:387-91. 2007....
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano LinfomiFrancesco Merli
Unità Operativa di Ematologia, Ospedale S Maria Nuova, Reggio Emilia, Italy
Haematologica 89:973-8. 2004..The aim of this study was to evaluate quality of life (QOL) in a group of elderly patients (> 65 years) with aggressive non-Hodgkin's lymphoma (NHL) treated with chemotherapy regimens containing anthracyclines...
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutationPaolo Aretini
Section of Oncogenetics, Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, University of Pisa, Pisa, Italy
Breast Cancer Res Treat 81:71-9. 2003..Proportion of ovarian cancer was increased in the 5' portion of BRCA1, and presence of prostate or pancreatic cancer in a family was correlated with presence of ovarian cancer in BRCA2...
Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policyFortunato Morabito
Centro Trapianti di Midollo Osseo, Dipartimento di Ematologia, Azienda Ospedaliera Bianchi Melacrino Morelli Via Melacrino, 89100 Reggio Calabria, Italy
Leuk Lymphoma 43:1933-8. 2002..In conclusion, the GISL definition of indolent disease is a reliable tool to design the appropriate therapeutic strategy in this histological setting...
Incidence of primary liver cancer in Italy between 1988 and 2002: an age-period-cohort analysisLuigino Dal Maso
Epidemiology and Biostatistics Unit, Aviano Cancer Center, IRCCS, Via Franco Gallini 2, 33081 Aviano PN, Italy
Eur J Cancer 44:285-92. 2008..Incidence of PLC over the last two decades in Italy did not substantially change but huge geographical variability emerged, mainly due to different times and modalities of spread of hepatitis C virus...
[Cancer incidence in Modena: 2002-2006 projections]Antonella Fracca
Registro tumori della Provincia di Modena
Epidemiol Prev 30:114-9. 2006..In particular, projected number of breast and prostate cancer cases is clearly overestimated due to diagnostic anticipation effect which gives rise to an excess in recent years...
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectKerry J Savage
Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
Blood 111:5496-504. 2008..Although the prognosis of ALK(-) ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course...
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutationsSimona Agata
Department of Oncology and Surgical Sciences, Oncology Section, University of Padua, Padua, Italy
Genes Chromosomes Cancer 45:791-7. 2006..11 < 0.19 < 0.28) of the BRCA1 mutation positive families. We conclude that the search for major genomic rearrangements is essential for an accurate and comprehensive BRCA1 mutation detection strategy in Italy...
Breast carcinoma survival in Europe and the United StatesMilena Sant
Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Cancer 100:715-22. 2004..Breast carcinoma survival rates were found to be higher in the U.S. than in Europe...
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemiasMaria Goldaniga
UO Ematologia e Centro Trapianti di Midollo, Ospedale Maggiore, IRCCS, University of Milan, Milan, Italy
Am J Hematol 83:349-54. 2008....
Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancerMaurie Markman
University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Gynecol Oncol 103:195-8. 2006..The relationship between survival and early changes in the serum level of the CA-125 antigen in patients with advanced ovarian cancer remains poorly defined...
Cancer incidence in eastern Libya: the first report from the Benghazi Cancer Registry, 2003Mufid El Mistiri
Benghazi Cancer Registry, Department of Oncology and Hematology, Garyounis University, Benghazi, Libya
Int J Cancer 120:392-7. 2007....
Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano LinformiFortunato Morabito
Centro Trapianti Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
Cancer 101:1601-8. 2004..To assess the impact of T-cell/B-cell phenotype on clinical outcome, the authors retrospectively compared patients who had peripheral T-cell lymphoma, unspecified (PTCL-U), with patients who had diffuse large B-cell lymphoma (DLBCL)...
Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim resultsFrancesco Sardanelli
University of Milan School of Medicine, Department of Medical and Surgical Sciences, Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy
Radiology 242:698-715. 2007....
Changes in breast cancer incidence and stage distribution in Modena, Italy: the effect of a mammographic screening programDaniela Turchetti
Cattedra e Divisione di Oncologia Medica, Policlinico di Modena, Italy
Cancer Causes Control 13:729-34. 2002..Overall, a decline in the average tumor diameter was shown (from 20.2 mm in 1992-1994 to 18 mm in 1996-1998). CONCLUSIONS: Our data confirm that mammographic screening leads to an increase in the incidence of early-stage BC cancers...
